Monday, June 6, 2011

Exelixis prostate cancer drug wows researchers, not Wall Street

While a melanoma-fighting drug from Roche and Berkeley’s Plexxikon Inc. seemed to steal the American Society of Clinical Oncology show this weekend, it was Exelixis Inc.’s prostate cancer treatment that made headlines Monday.
Not for all the right reasons, though.

No comments:

Post a Comment